Zhejiang Younuo Jin Bioengineering

Zhejiang Younuojin Bioengineering is a Chinese biotechnology company specializing in the research, development, and manufacturing of long-acting recombinant protein therapeutics. Founded in 2009 and led by founder Lin Dianhai, the company leverages its proprietary Human Serum Albumin (HSA) fusion protein technology platform to extend the half-life of therapeutic proteins and hormones. Its lead candidate is a recombinant growth hormone-albumin fusion protein (HSA-rhGH), which is currently in Phase 3 clinical development for growth hormone deficiency and growth disorders. In late 2025, the company expanded its footprint by launching a highly automated, unmanned 'black light factory' manufacturing base in Tianjin to support the commercial production of its long-acting biologics pipeline.